LINCLATAMIG
UNII 4NHP5YXY4Z

Substance Identification & Data

This profile provides standardized clinical and technical data for Linclatamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 4NHP5YXY4Z.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2885203-43-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

4NHP5YXY4Z

CAS Registry Number

2885203-43-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LINCLATAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C206931

National Cancer Institute reference terminology for clinical and research data.

INN ID

13026

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Linclatamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LINCLATAMIG

Common Names & Synonyms

H-GAMMA1 HEAVY CHAIN ANTI-LY6G6D HUMANIZED, G1V84-1 VH E44, CH1 K86 (1-442) (VH E44 (HOMO SAPIENS IGHV3-23*01 (77.6%) -(IGHD) -IGHJ2*01 (92.3%) R120>P (104), CDR-IMGT (8.8.5) (26-33.51-58.97-101)) (1-112) -HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1, CH1 K120, CH3 E12, M14, CH1 K86, G1V30 CH2 G84.4, G1V32 CH3 W22 (KNOB) (CH1 R120>K (209), S86>K (178) (113-210), HINGE 1-15 (211-225), CH2 N84.4>G (292) (226-335), CH3 E12 (351), M14 (353), T22>W (361) (336-440), CHS (441-442)) (123-442)), (215-218')-DISULFIDE WITH L-KAPPA LIGHT CHAIN HUMANIZED, KV84-1 VK K44, CK E22 (1'-218') (V-KAPPA K44 (HOMO SAPIENS IGKV1-5*01 (89.8%) -IGKJ4*01 (100%), CDR-IMGT (6.3.13) (27'-32'.50'-52'.89'-101')) (1'-111') -HOMO SAPIENS IGKC*01 (99.1%) V22>E (137), KM3 A45.1 (157), V101 (195) (112'-218'))

IMMUNOGLOBULIN G1 (39-LYSINE,185-GLUTAMIC ACID,299-GLYCINE,368-SERINE,370-ALANINE,409-VALINE), ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HUMAN-MUS MUSCULUS CLONE 38E4V1-MD1 .GAMMA.1-CHAIN) DISULFIDE WITH (44-GLUTAMIC ACID,138-LYSINE) HUMAN-MUS MUSCULUS CLONE 38E4V1-MD1 .KAPPA.-CHAIN, (228->221'),(231->224')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (39-GLUTAMIC ACID,178-LYSINE,292-GLYCINE,361-TRYPTOPHAN) ANTI-(HUMAN LYMPHOCYTE ANTIGEN LY6G6D) (HUMAN-ORYCTOLAGUS CUNICULUS CLONE 20A12.QNTV12 .GAMMA.1-CHAIN) DISULFIDE WITH (38-LYSINE,137-GLUTAMIC ACID) HUMAN-ORYCTOLAGUS CUNICULUS CLONE 20A12.QNTV12 .KAPPA.-CHAIN

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS LY6G6D (LYMPHOCYTE ANTIGEN 6 FAMILY MEMBER G6D, G6D, LY6-D, MEGT1, NG25)) AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC

LINCLATAMIG [INN]

External Clinical & Regulatory Resources

Previous UNII4NHO2K4K5B

Next UNII4NHS962LCE